Search
Cytokinetics Inc
CYTKAdd to Watchlist
74.130USD
+0.680+0.93%
Close 08-14 16:00（ET）Quotes delayed by 15 min
10.31BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Cytokinetics Inc is 8.18, ranking 162 out of 387 in the Biotechnology & Medical Research industry. The average price target is 79.00, with a high of 120.00 and a low of 55.00.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
110.263
Target Price
+48.74%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Cytokinetics Inc
CYTK
22
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cytokinetics Inc's expected revenue for the next quarter?
Cytokinetics Inc's expected revenue is 39.25M.
What is Cytokinetics Inc's price target?
Analysts forecast that Cytokinetics Inc's price target is USD 79.00, with the highest forecast at USD 120.00 and the lowest forecast at USD 55.00.
How have Cytokinetics IncCYTK's recent earnings per share performed?
The market expectation was USD -1.50, while Cytokinetics IncCYTK's earnings per share (EPS) for the previous quarter was USD -1.67. EPS for the next quarter is expected at USD -1.48.
What is the analyst rating for Cytokinetics Inc?
Based on the ratings of Cytokinetics Inc's stock from 22 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.